•
Jun 30, 2023

Enfusion Q2 2023 Earnings Report

Enfusion reported a balanced quarter with revenue growth and improved profitability.

Key Takeaways

Enfusion reported a balanced quarter with a 16.9% year-over-year revenue growth, driven by increasing client add counts, bookings, and average contract value, despite macroeconomic challenges.

Signed a 20-billion-dollar active ETF fund manager and a public investment arm of a global private equity firm.

Delivered significant margin expansion through operational efficiencies and cost control.

Improved client add counts with 39 new clients, up from 27 in the previous quarter.

Increased average contract value and 2Q bookings growth increased 44% sequentially.

Total Revenue
$42.7M
Previous year: $36.5M
+16.9%
EPS
$0.01
Previous year: -$0.03
-133.3%
Gross Profit
$28.5M
Previous year: $25.7M
+11.0%
Cash and Equivalents
$27.8M
Previous year: $57M
-51.3%
Free Cash Flow
$3.8M
Previous year: $798K
+376.1%
Total Assets
$94.1M
Previous year: $110M
-14.6%

Enfusion

Enfusion

Enfusion Revenue by Segment

Forward Guidance

Enfusion anticipates revenue between $170 million and $175 million, and adjusted EBITDA between $30 million and $32 million for 2023.

Revenue & Expenses

Visualization of income flow from segment revenue to net income